Downregulation of miR-519a Predicts Poor Prognosis and Contributes to Tumor Progression in Gastric Cancer

• Published in: Oncology research and treatment Vol. 43; no. 1-2; p. 19
• Main Authors: Cai, Huimei, Lin, Hui, Cao, Wenyu, Sun, Juan, Huang, Yudian, Fang, Yuehua
• Format: Journal Article
• Language: English
• Published: Netherlands 01.02.2020
• Subjects: MiR-519a; Prognosis; Proliferation; Gastric cancer; Migration; Invasion
• ISSN: 2296-5262
• DOI: 10.1159/000504054

MicroRNAs (miRNAs) have been demonstrated to be involved in the pathogenesis of various human cancers. However, the role of microRNA-519a (miR-519a) in gastric cancer (GC) remains unclear. This study aimed to investigate the clinical value and biological function of miR-519a in GC. The expression of miR-519a in GC tissues and cell lines was estimated by quantitative real-time polymerase chain reaction. Survival analysis for GC patients was performed using the Kaplan-Meier method. Cox regression analysis was used to confirm the prognostic value of miR-519a. The biological function and potential targets of miR-519a in GC progression were assessed using cell experiments. In this study, we found that miR-519a was an important tumor suppressor with downregulated expression in GC tissues and cells compared with that in normal controls (all p < 0.05). MiR-519a expression was inversely correlated with differentiation, lymph node metastasis, and the TNM stage of patients. Decreased miR-519a expression was associated with the poor overall survival of GC patients (log-rank p = 0.002) and served as an independent prognostic biomarker for the patients. The in vitro analyses indicated that miR-519a overexpression in GC cells resulted in inhibited cell proliferation, migration, and invasion, and IGFBP1 was determined to be a direct target of miR-519a. All the data in the present study revealed that the downregulated expression of miR-519a predicts the poor prognosis of GC and is involved in the regulation of GC progression. We consider that miR-519a may be a candidate therapeutic target for GC treatment.